News

2024 a transformational year of progress: A note from the CEO 20 December 2024
Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer 9 October 2024
Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board 2 October 2024
Curve Therapeutics strengthens Leadership Team with appointment of experienced biotech executive Simon Jones 9 July 2024
Research published in Journal of the American Chemical Society highlights potential of HIF Inhibition as a therapeutic approach for cancers 26 March 2024
Curve Therapeutics April 2024 Conference Attendance 21 March 2024
Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline 27 February 2024
Curve Therapeutics appoints Dr Sally Price as Vice President of Biology 18 September 2023
Curve Therapeutics Expands Leadership Team and Scientific Advisory Board: Dr Monika Ermann appointed Vice President Drug Discovery to advance Curve’s therapeutic programmes directed at challenging cancer targets 2 May 2023
Curve CSO featured in the “Careers in Drug Discovery” podcast 18 January 2023
Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform 16 February 2022
Curve Therapeutics Participates in Parliamentary Meetings 8 September 2021
Curve Therapeutics Announces Grant of US Patent 31 March 2021
Curve Therapeutics Announces Investment from co-lead Epidarex Capital 31 July 2020
Curve Therapeutics Announces Seed Investment from Advent Life Sciences 27 June 2019